AstraZeneca Hits Estimates, But GAAP Results Lag Last Year's
AstraZeneca (ISE: AZN) reported earnings on Aug. 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), AstraZeneca met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank. Non-GAAP earnings per share dropped significantly. GAAP earnings per share shrank significantly.
Margins dropped across the board.
AstraZeneca booked revenue of $6.23 billion. The 18 analysts polled by S&P Capital IQ foresaw sales of $6.23 billion on the same basis. GAAP reported sales were 6.4% lower than the prior-year quarter's $6.66 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at $1.20. The nine earnings estimates compiled by S&P Capital IQ predicted $1.20 per share. Non-GAAP EPS of $1.20 for Q2 were 22% lower than the prior-year quarter's $1.53 per share. GAAP EPS of $0.66 for Q2 were 48% lower than the prior-year quarter's $1.27 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 78.9%, 100 basis points worse than the prior-year quarter. Operating margin was 19.3%, much worse than the prior-year quarter. Net margin was 13.2%, much worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $6.43 billion. On the bottom line, the average EPS estimate is $1.30.
Next year's average estimate for revenue is $26.17 billion. The average EPS estimate is $5.23.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 45 members out of 50 rating the stock outperform, and five members rating it underperform. Among two CAPS All-Star picks (recommendations by the highest-ranked CAPS members), two give AstraZeneca a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AstraZeneca is hold, with an average price target of $50.55.
Can your portfolio provide you with enough income to last through retirement? You'll need more than AstraZeneca. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add AstraZeneca to My Watchlist.
The article AstraZeneca Hits Estimates, But GAAP Results Lag Last Year's originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.